Immatics Presents PRAME Therapy Data at ESMO Meeting
By United One News · AI-generated summary of 2 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
Immatics presented updated clinical trial data for its IMA402 bispecific and IMA203CD8 cell therapy programs targeting advanced solid tumors at the ESMO meeting on October 24, 2026.
- Immatics shared updated clinical data from an ongoing Phase 1b study involving the IMA402 PRAME bispecific.
- The company also presented findings from a Phase 1 study evaluating the IMA203CD8 PRAME cell therapy.
- Both presentations highlighted the clinical activity of these therapies across various advanced solid tumors.
Covered by 3 outlets across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Timeline
First to report: Globenewswire_fr (); 3 articles from 2 outlets so far.
Who is covering this story
- Center (2): Globenewswire_fr, Pharmabiz
Sources
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting — Globenewswire_fr (center, AI-estimated) ·
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting — Globenewswire_fr (center, AI-estimated) ·
- AskBio announces 5 presentations at the European Society of Gene and Cell Therapy 33rd Annual Congress — Pharmabiz (center, AI-estimated) ·